ABSTRACT
PURPOSE: In this study, patients with epilepsy with eyelid myoclonia (E-EM) were evaluated according to their EEG findings, seizure outcomes, and their consistency with the final ictal EEG findings. We also investigated the possible prognostic factors. METHODS: Patients with E-EM and at least two years of follow-up in our clinic were included in the study. We analyzed the presence of eyelid myoclonia, absence and myoclonic seizures, and generalized tonic-clonic seizures for the prior two years and then verified with the latest ictal EEG features. Video-EEGs were analyzed according to the background activity, the existence of generalized spike-wave discharge or polyspike-wave complexes, focal spike-wave discharge, photoparoxysmal responses, and fast activity. RESULTS: 21 patients were involved in this study. In six patients, the seizures were undetected on the first EEGs, whereas they were detected on subsequent ones. The seizures were captured on the first EEGs of six patients; however, they disappeared on subsequent ones. Only one patient had seizures detected on every EEG. The consistency of the seizures was variable in eight patients. At the final follow-up, seizures were reported as being under control for more than two years in 12 patients, according to patients and their parents' reports. However, ictal EEG findings were detected in six of these patients. No electroclinical feature was associated with seizure freedom. CONCLUSION: This study provides further evidence that seizure freedom in E-EM patients is overestimated. The patients and their parents may not be aware of the seizures. Therefore, video-EEG monitorization is essential during follow-up.
Subject(s)
Electroencephalography , Seizures , Humans , Male , Female , Adult , Adolescent , Young Adult , Child , Seizures/physiopathology , Seizures/diagnosis , Seizures/complications , Myoclonus/physiopathology , Myoclonus/diagnosis , Myoclonus/etiology , Middle Aged , Eyelids/physiopathology , Video Recording , Child, Preschool , Follow-Up Studies , Epilepsies, Myoclonic/physiopathology , Epilepsies, Myoclonic/complications , Epilepsies, Myoclonic/diagnosis , Retrospective Studies , Epilepsy/physiopathology , Epilepsy/complications , Epilepsy/diagnosisABSTRACT
BACKGROUND AND PURPOSE: To test the hypothesis that myoclonic seizures can evolve to tonic seizures, we documented the electroclinical features of this under-recognized seizure type. METHODS: We observed a distinct seizure pattern starting with myoclonus without returning to an interictal state, which subsequently evolved into generalized tonic seizures. The detailed symptomatic and electroencephalographic characteristics of this seizure were extracted, and the clinical manifestations, drug curative responses in patients with this seizure were reviewed and analyzed. RESULTS: The onset of all seizures was characterized by a preceding period of myoclonus and bursts of generalized spike or poly-spike slow wave discharges with high amplitude. This was closely followed by the occurrence of tonic seizures, which were distinguished by bursts of generalized fast activity at 10 Hz or higher frequency. This under-recognized seizure type has been designated as myoclonic-to-tonic (MT) seizure. The number of patients identified with MT seizures in this study was 34. The prevalence rate of MT seizures was found to be higher in males. While MT seizures typically included a tonic component, it should be noted that some patients experiencing this seizure type never presented with isolated tonic seizures. Generalized Epilepsy not further defined (GE) accounted for approximately one-third of the diagnosed cases, followed by Lennox-Gastaut syndrome and Epilepsy with Myoclonic-Atonic seizures. In comparison to other types of epilepsy, GE with MT seizures demonstrated a more favorable prognosis. CONCLUSIONS: The classification of myoclonic-to-tonic seizure represents a novel approach in comprehending the ictogenesis of generalized seizures and can provide valuable assistance to clinicians in epilepsy diagnosis.
Subject(s)
Electroencephalography , Epilepsies, Myoclonic , Seizures , Humans , Male , Female , Electroencephalography/methods , Adult , Adolescent , Seizures/physiopathology , Seizures/diagnosis , Child , Young Adult , Epilepsies, Myoclonic/physiopathology , Epilepsies, Myoclonic/diagnosis , Epilepsy, Generalized/physiopathology , Epilepsy, Generalized/diagnosis , Child, Preschool , Middle Aged , Myoclonus/physiopathology , Myoclonus/diagnosis , InfantABSTRACT
PURPOSE: New-onset refractory status epilepticus (NORSE) is defined as a state of prolonged seizure activity that does not improve despite the appropriate administration of medications, with underlying causes unknown after the initial diagnosis of status epilepticus. Because episodes of NORSE are accompanied by severe complications and a high risk of mortality, the prompt identification of the underlying cause is crucial for effective treatment and outcome prediction. This study assessed the relationship of NORSE etiologies with baseline clinical features in pediatric population. METHODS: Seventy-one pediatric patients, under 18 years of age at the initial diagnosis (4.50 ± 4.04, mean ± standard deviation), who experienced at least one episode of NORSE and underwent a comprehensive diagnostic evaluation between January 2005 and June 2020 at our center, were retrospectively selected. We reviewed clinical features at disease onset and long-term follow-up data. Uniform manifold approximation and projection (UMAP) was used to distinguish etiological clusters according to baseline clinical characteristics, and further analysis was performed based on underlying etiologies. RESULTS: Two distinct etiological groups-genetic and non-genetic-were identified based on the UMAP of clinical characteristics. Dravet syndrome (12/15, 80%) was more predominant in patients with a genetic diagnosis, whereas cryptogenic NORSE and encephalitis were prevalent in patients without a genetic diagnosis. The analysis of etiological categories revealed that age at the onset of status epilepticus (P=0.021) and progression to super refractory status epilepticus (SRSE) (P=0.038) were independently associated with differences in etiologies. CONCLUSION: Several clinical features in patients with NORSE, including the age of onset and the development of SRSE, can help identify underlying causes, which necessitate prompt and adequate treatment.
Subject(s)
Drug Resistant Epilepsy , Status Epilepticus , Humans , Status Epilepticus/diagnosis , Status Epilepticus/etiology , Male , Retrospective Studies , Female , Child, Preschool , Child , Infant , Drug Resistant Epilepsy/diagnosis , Adolescent , Encephalitis/diagnosis , Encephalitis/complications , Epilepsies, Myoclonic/diagnosis , Epilepsies, Myoclonic/physiopathologyABSTRACT
OBJECTIVE: Giant somatosensory evoked potentials (SEPs) are observed in patients with cortical myoclonus. Short-latency components (SLC), are regarded as evoked epileptic activities or paroxysmal depolarization shifts (PDSs). This study aimed to reveal the electrophysiological significance of the middle-latency component (MLC) P50 of the SEPs. METHODS: Twenty-two patients with cortical myoclonus having giant SEPs (patient group) and 15 healthy controls were included in this study. Waveform changes in SEPs before and after perampanel (PER) treatment were evaluated in the patient group. The wide range, time-frequency properties underlying the waveforms were compared between the groups. RESULTS: After PER treatment, SLC was prolonged and positively correlated with PER concentration, whereas MLC showed no correlation with PER concentration. Time-frequency analysis showed a power increase (156 Hz in all patients, 624 Hz in benign adult familial myoclonus epilepsy patients) underlying SLC and a power decrease (156 Hz, 624 Hz) underlying MLC in the patient group. CONCLUSIONS: The high-frequency power increase in SLCs and decrease in MLCs clearly reflected PDS and subsequent hyperpolarization, respectively. This relationship was similar to that of interictal epileptiform discharges, suggesting that giant SEPs evoke epileptic complexes of excitatory and inhibitory components. SIGNIFICANCE: MLCs of giant SEPs reflected inhibitory components.
Subject(s)
Evoked Potentials, Somatosensory , Humans , Evoked Potentials, Somatosensory/physiology , Male , Female , Adult , Electroencephalography/methods , Young Adult , Adolescent , Anticonvulsants/therapeutic use , Anticonvulsants/pharmacology , Middle Aged , Pyridones/therapeutic use , Epilepsies, Myoclonic/physiopathology , Epilepsies, Myoclonic/diagnosis , NitrilesABSTRACT
OBJECTIVE: To evaluate the clinical predictors of positive genetic investigation in developmental and epileptic encephalopathies, beyond the influence of Dravet Syndrome. METHODS: The study included 98 patients diagnosed with developmental and epileptic encephalopathies. The patients underwent Sanger sequencing of SCN1A, Chromosomal Microarray Analysis, and Whole Exome Sequencing. The association of clinical variables with a positive genetic test was investigated using univariate and multivariate analysis. RESULTS: Genetic diagnosis was identified in 47 (48 %) patients with developmental and epileptic encephalopathies. Beyond Dravet Syndrome influence, first seizure in the context of fever (p < 0.01), seizures precipitated by temperature (p = 0.04), cognitive regression (p = 0.04), hypotonia (p < 0.01), and focal seizures (p = 0.03) increased the chances of a positive genetic investigation. In contrast, atonic seizures (p = 0.01) and generalized discharges on electroencephalogram (p = 0.02) decreased the chances. Dravet Syndrome was positively associated with a genetic developmental and epileptic encephalopathies etiology (p < 0.01), whereas epilepsy with myoclonic-atonic seizures (p = 0.01), developmental and epileptic encephalopathies with spike-wave activation in sleep (p = 0.04), and Lennox-Gastaut syndrome (p = 0.03) were negatively associated. In multivariate analysis, the first seizure in the context of fever (p < 0.01) and hypotonia (p = 0.02) were positively, and atonic seizures (p = 0.01) were negatively and independently associated with a genetic etiology. CONCLUSION: The predictive variables of genetic investigation in developmental and epileptic encephalopathies are first seizure in the context of fever and hypotonia, whereas atonic seizures decrease the chances of finding a genetic cause for developmental and epileptic encephalopathies. Regarding epileptic syndromes, Dravet Syndrome is highly associated with a positive genetic test, whereas epilepsy with myoclonic-atonic seizures, developmental and epileptic encephalopathies with spike-wave activation in sleep, and Lennox-Gastaut syndrome are rarely associated with a positive genetic investigation.
Subject(s)
Epilepsies, Myoclonic , NAV1.1 Voltage-Gated Sodium Channel , Humans , Male , Female , Child , Child, Preschool , Epilepsies, Myoclonic/genetics , Epilepsies, Myoclonic/diagnosis , NAV1.1 Voltage-Gated Sodium Channel/genetics , Infant , Adolescent , Electroencephalography , Genetic Testing , Adult , Epilepsy/genetics , Epilepsy/diagnosis , Epilepsy/physiopathology , Young Adult , Exome Sequencing , Lennox Gastaut Syndrome/genetics , Lennox Gastaut Syndrome/diagnosisABSTRACT
BACKGROUND: Dravet Syndrome (DS) is a rare and severe form of childhood epilepsy that is often refractory to conventional antiepileptic drugs. Emerging evidence suggests that Cannabidiol (CBD) offer therapeutic benefits for DS. This review aims to evaluate the efficacy and safety of CBD in pediatric patients with DS based on data from ten clinical trials. METHODS: A review was conducted to identify clinical trials assessing the efficacy and safety of CBD in pediatric patients diagnosed with DS. PubMed, MEDLINE, Scopus, Web of Science, and relevant grey literature were systematically searched for relevant articles up to October 2023, and clinical trials within the last 10 years were included. The search strategy incorporated controlled vocabulary terms and keywords related to "Cannabidiol," "Dravet Syndrome," and "pediatric patients." RESULTS: The analysis revealed promising efficacy outcomes. Notably, CBD demonstrated substantial reductions in seizure frequency, with some patients achieving seizure freedom. The findings emphasised the consistency of CBD's efficacy across different patient subgroups. The safety profile of CBD was generally acceptable, with adverse events often being manageable. CONCLUSION: This review consolidates evidence from multiple clinical trials, affirming the potential of CBD as a promising treatment option for pediatric patients with DS. While further research is needed to address existing knowledge gaps, CBD's efficacy and acceptable safety profile make it a valuable addition to the therapeutic tools for DS.
Subject(s)
Cannabidiol , Epilepsies, Myoclonic , Lennox Gastaut Syndrome , Child , Humans , Anticonvulsants , Cannabidiol/therapeutic use , Epilepsies, Myoclonic/diagnosis , Epilepsies, Myoclonic/drug therapy , Lennox Gastaut Syndrome/drug therapy , Lennox Gastaut Syndrome/diagnosis , Seizures/drug therapyABSTRACT
Myoclonic-tonic (MT) and spasm-tonic (ST) seizures represent distinctive features in late infantile epileptic encephalopathy (LIEE). This commentary aims to delineate the electroclinical characteristics of MT and ST seizures, setting them apart from other seizure types. Our analysis encompasses 211 ST and MT seizures observed in 31 patients diagnosed with LIEE, providing a comprehensive overview of video-EEG features and polygraphic signatures. In MT seizures, EEG findings reveal a high-voltage diffuse spike/polyspike and wave discharge, often succeeded by diffuse electrodecrements. The amplitude-integrated EEG (aEEG) signature is described as a "reversed checkmark." Conversely, ST seizures exhibit EEG findings such as a vertex positive deflection after a slow-wave and relative electrodecrement, with intermixed epileptiform discharges. In comparison to MT seizures, polygraphic characteristics in ST seizures appear more distinct, featuring a brief rhomboid shape corresponding to the spasm, followed by a lengthier rectangular shape indicative of the tonic phase of the ST seizure. While the pathophysiology of ST and MT seizures remains inadequately understood, their concurrent occurrence and association with other seizure types (tonic, epileptic spasm, myoclonic) within the temporal context of LIEE and other epileptic encephalopathies prompt us to anticipate advancements in our understanding through future research. We hope that this study serves as a foundation for unraveling these complexities in the times to come.
Subject(s)
Electroencephalography , Epilepsies, Myoclonic , Seizures , Humans , Electroencephalography/methods , Epilepsies, Myoclonic/physiopathology , Epilepsies, Myoclonic/diagnosis , Seizures/physiopathology , Seizures/diagnosis , Infant , Child, Preschool , Child , Spasms, Infantile/physiopathology , Spasms, Infantile/diagnosis , Male , FemaleABSTRACT
Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare developmental and epileptic encephalopathies associated with seizure and nonseizure symptoms. A comprehensive understanding of how many individuals are affected globally, the diagnostic journey they face, and the extent of mortality associated with these conditions is lacking. Here, we summarize and evaluate published data on the epidemiology of DS and LGS in terms of prevalence, incidence, diagnosis, genetic mutations, and mortality and sudden unexpected death in epilepsy (SUDEP) rates. The full study protocol is registered on PROSPERO (CRD42022316930). After screening 2172 deduplicated records, 91 unique records were included; 67 provided data on DS only, 17 provided data on LGS only, and seven provided data on both. Case definitions varied considerably across studies, particularly for LGS. Incidence and prevalence estimates per 100 000 individuals were generally higher for LGS than for DS (LGS: incidence proportion = 14.5-28, prevalence = 5.8-60.8; DS: incidence proportion = 2.2-6.5, prevalence = 1.2-6.5). Diagnostic delay was frequently reported for LGS, with a wider age range at diagnosis reported than for DS (DS, 1.6-9.2 years; LGS, 2-15 years). Genetic screening data were reported by 63 studies; all screened for SCN1A variants, and only one study specifically focused on individuals with LGS. Individuals with DS had a higher mortality estimate per 1000 person-years than individuals with LGS (DS, 15.84; LGS, 6.12) and a lower median age at death. SUDEP was the most frequently reported cause of death for individuals with DS. Only four studies reported mortality information for LGS, none of which included SUDEP. This systematic review highlights the paucity of epidemiological data available for DS and especially LGS, demonstrating the need for further research and adoption of standardized diagnostic criteria.
Subject(s)
Epilepsies, Myoclonic , Lennox Gastaut Syndrome , Humans , Lennox Gastaut Syndrome/epidemiology , Epilepsies, Myoclonic/genetics , Epilepsies, Myoclonic/epidemiology , Epilepsies, Myoclonic/diagnosis , Epilepsies, Myoclonic/mortality , Prevalence , Incidence , Sudden Unexpected Death in Epilepsy/epidemiology , Global Health/statistics & numerical dataABSTRACT
BACKGROUND: Dravet syndrome is a rare infantile onset epilepsy syndrome encompassing treatment resistant epilepsy and neurodevelopmental difficulties. There is limited data regarding caregiver experiences of diagnosis, treatment and supports for the associated neurodevelopmental problems. METHOD: Semi-structured interviews were conducted with caregivers of 36/48 children (75% of total population in Sweden) with Dravet syndrome. Data was analysed using thematic analysis. RESULTS: Regarding the diagnostic experience, themes were: Delays in diagnostic process, genetic testing not optimal, communication of Dravet syndrome diagnosis and support and information soon after diagnosis. Caregivers felt that delays in diagnosis and testing could have been avoided whilst experiences of communication of diagnosis and support after diagnosis varied. In terms of treatment for seizures, the themes were: Satisfied with treatment, emergency treatment, treatment with antiseizure medications, strategies to control seizures via temperature regulation/avoidance of infections and use of equipment and aids. Caregivers were in the main accepting that seizures in Dravet syndrome are very difficult to treat and that seizure freedom is often an unachievable goal. Many felt frustrated that they were expected to take responsibility with respect to choice of medication. They often employed strategies (e.g., avoidance of physical activity) to reduce seizures or their impact. In terms of supports for neurodevelopmental problems, the themes were: Struggled to access support, lack of integrated healthcare and satisfaction with school. Many caregivers felt that accessing necessary supports for their children and developmental and behavioural needs was a struggle and that the provision of support often lacked integration e.g., lack of collaboration between child's disability service and school. Caregivers also expressed a desire that there would be better knowledge of Dravet syndrome in emergency departments and schools, that care would be better integrated and that there would be more supports for assessment and interventions regarding the associated neurodevelopmental problems. CONCLUSION: The responses of caregivers of children with Dravet syndrome highlight the need for supports from diagnosis for both epilepsy and neurodevelopmental problems. Good examples of provision were identified but parents often felt they lacked support and support often came from providers who lacked knowledge of the syndrome. Collaboration between medical, disability and school services was often lacking.
Subject(s)
Epilepsies, Myoclonic , Epilepsy , Epileptic Syndromes , Humans , Child , Caregivers , Epilepsy/complications , Epilepsy/diagnosis , Epilepsy/therapy , Epilepsies, Myoclonic/complications , Epilepsies, Myoclonic/diagnosis , Epilepsies, Myoclonic/therapy , SeizuresABSTRACT
Dravet syndrome is a severe form of epilepsy characterised by recurrent seizures and cognitive impairment. It is mainly caused by variant in the SCN1A gene in 90% of cases, which codes for the α subunit of the voltage-gated sodium channel. In this study, we present one suspected case of Dravet syndrome in Moroccan child that underwent exome analysis and were confirmed by Sanger sequencing. The variant was identified in the SCN1A gene, and is a new variant that has never been described in the literature. The variant was found de nova in our case, indicating that it was not inherited from the parents. The variant, SCN1A c.965-2A>G p.(?), is located at the splice site and results in an unknown modification of the protein. This variant is considered pathogenic on the basis of previous studies. These results contribute to our knowledge of the SCN1A gene mutations associated with Dravet syndrome and underline the importance of genetic analysis in the diagnosis and confirmation of this disorder. Further studies are needed to better understand the functional consequences of this variant and its implications for therapeutic strategies in Dravet syndrome.
Subject(s)
Epilepsies, Myoclonic , Epilepsy , Child , Humans , Epilepsies, Myoclonic/genetics , Epilepsies, Myoclonic/diagnosis , NAV1.1 Voltage-Gated Sodium Channel/genetics , Epilepsy/genetics , Mutation/genetics , Sequence Analysis , SeizuresABSTRACT
Dravet syndrome (DS), also known as severe myoclonic epilepsy of infancy, is a rare and drug-resistant form of developmental and epileptic encephalopathies, which is both debilitating and challenging to manage, typically arising during the first year of life, with seizures often triggered by fever, infections, or vaccinations. It is characterized by frequent and prolonged seizures, developmental delays, and various other neurological and behavioral impairments. Most cases result from pathogenic mutations in the sodium voltage-gated channel alpha subunit 1 (SCN1A) gene, which encodes a critical voltage-gated sodium channel subunit involved in neuronal excitability. Precision medicine offers significant potential for improving DS diagnosis and treatment. Early genetic testing enables timely and accurate diagnosis. Advances in our understanding of DS's underlying genetic mechanisms and neurobiology have enabled the development of targeted therapies, such as gene therapy, offering more effective and less invasive treatment options for patients with DS. Targeted and gene therapies provide hope for more effective and personalized treatments. However, research into novel approaches remains in its early stages, and their clinical application remains to be seen. This review addresses the current understanding of clinical DS features, genetic involvement in DS development, and outcomes of novel DS therapies.
Subject(s)
Epilepsies, Myoclonic , Epilepsy, Generalized , Epilepsy , Humans , Precision Medicine , Epilepsies, Myoclonic/diagnosis , Epilepsies, Myoclonic/genetics , Epilepsies, Myoclonic/therapy , SeizuresABSTRACT
Las encefalopatías epilépticas es un grupo de síndromes epilépticos caracterizados por el deterioro cognitivo más allá de lo esperado debido a la actividad epiléptica. Se caracterizan por presentar resistencia farmacológica grave, electroencefalogramas profundamente anormales, inicio en la niñez temprana, deterioro neurocognitivo, fenotipo variable y resonancia magnética de cerebro usualmente normal. Frecuentemente estos síndromes están genéticamente determinados. Su diagnóstico correcto y oportuno puede contribuir y guiar el consejo médico y terapia adecuada, influyendo así en el pronóstico a corto, mediano y largo plazo. En este artículo se revisan los hallazgos electroencefalográficos, genéticos y opciones terapéuticas más recomendadas, facilitando así la conducta clínica. Las encefalopatías epilépticas incluidas en este artículos abarcan los síndromes de Ohtahara, encefalopatia mioclónica temprana, epilepsia focal migratoria de la infancia, West, Dravet, estado mioclónico en encefalopatías no progresivas, Doose, Lennox-Gastaut, Landau-Kleffner y epilepsia con espiga-onda continuas durante el sueño de onda lenta.
Epileptic encephalopathies is a group of epileptic syndromes characterized by progressive cognitive impairment beyond the expected for the epilepsy activity. They are characterized by severe pharmaco-resistant epilepsy, severely abnormal electroencephalograms, early-age onset, neurocognitve impairment, variable phenotype and usually normal brain MRI. These syndromes are usually genetically determined. A correct and timely diagnosis could help and guide the medical counselling and the correct therapeutic approach improving the short, medium and long term outcomes. In this article we review the electroencephalographic and genetic findings along with the most recommended therapeutic options facilitating the clinical management. We include the following epileptic encephalopathy syndromes: Ohtahara, early myoclonic encephalopathy, epilepsy of infancy with migrating focal seizures, West, Dravet, non-progressive myoclonic status, Doose, Lennox-Gastaut, Landau-Kleffner and continuous spike-wave during sleep epilepsy.
Subject(s)
Humans , Spasms, Infantile , Brain Diseases/genetics , Epilepsies, Myoclonic/genetics , Syndrome , Brain Diseases/classification , Brain Diseases/diagnosis , Brain Diseases/drug therapy , Epilepsies, Myoclonic/diagnosis , Epilepsies, Myoclonic/drug therapy , Electroencephalography , Anticonvulsants/classification , Anticonvulsants/therapeutic useABSTRACT
Objetivo: Describir las principales características clínicas y evolutivas de una serie de pacientes con epilepsia de difícil control, tratados con altas dosis de dexametasona intravenosa.Métodos: Se realizó un estudio descriptivo con una serie de 12 casos tratados por epilepsia de difícil control en el Servicio de Neuropediatría del Hospital Pediátrico Docente Juan Manuel Márquez de enero de 2010 a septiembre de 2018. Se les administró dexametasona intravenosa a altas dosis en tres días consecutivos cada mes(ciclo) y durante cinco meses, además de los fármacos antiepilépticos que tenían indicados. Se analizó la edad de inicio de la epilepsia y al diagnóstico, la edad al inicio del tratamiento, el tipo de crisis y de epilepsia, el tiempo entre el inicio de la epilepsia y el tratamiento y, además, la causa. Se utilizó el test exacto de Fisher para la determinación de la asociación entre estas dos últimas variables y la evolución clínica.Resultados: Predominaron los pacientes del sexo masculino, los que iniciaron lasmanifestaciones clínicas en el primer año de vida, aquellos que presentaron varios tipos de crisis, los que usaban politerapia y tenían una causa conocida de la epilepsia (sintomática). Luego de los cinco ciclos de tratamiento, se detectó una evolución satisfactoria (disminuyó en al menos 50 Por ciento la frecuencia de las crisis) en 8 de 12 enfermos. Solo en dos casos se presentaron reacciones adversas al tratamiento (hipertensión arterial), que no requirieron la retirada de la terapéutica.Conclusiones: Hubo predominio en los pacientes con varios tipos de crisis epilépticas y en los que la causa de la epilepsia fue reconocida (estructural). En ellos, el uso de la dexametasona intravenosa a altas dosis, añadido a otros fármacos antiepilépticos, fueuna alternativa eficaz para disminuir la frecuencia de las crisis epilépticas(AU)
Objective: To describe the main clinical and evolutionary characteristics of a series of patients with difficult control epilepsy treated with high doses of intravenous dexamethasone.Methods: A descriptive study was conducted with a series of 12 cases treated for difficult control epilepsy in the Neuropediatric Service at Juan Manuel Márquez Pediatric Teaching Hospital from January 2010 to September 2018. They receivedintravenous dexamethasone at high doses on 3 consecutive days each month (cycle) and for five months, in addition to the antiepileptic drugs they had indicated. This study analyzed the ages at epilepsy onset and at diagnosis, at the beginning of treatment, the type of seizures and epilepsy, the time between the epilepsy onset and treatment and, inaddition, the cause. The fisher exact test was used to determine the association between these last two variables and the clinical evolution.Results: Male patients predominated, those who started clinical manifestations in the first year of life, those who presented several types of seizures, those who used polytherapy and had a known cause of epilepsy (symptomatic). After five treatment cycles, a satisfactory evolution was detected. The frequency of seizures decreased by at least 50 Per cent in 8 of 12 patients. Only in two cases showed adverse reactions to the treatment (arterial hypertension), which did notrequire the withdrawal of the therapy.Conclusions: There was a predominance of patients with several types of epilepticseizures and of those that the cause of epilepsy was recognized as structural. In them, the use of intravenous dexamethasone at high doses, added to other antiepileptic drugs, was an effective alternative to reduce the frequency of epileptic seizures(AU)
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Cuba/epidemiology , Epilepsy/diagnosis , Epilepsy/drug therapy , Epilepsy/epidemiology , Epilepsies, Myoclonic/diagnosis , Epilepsies, Myoclonic/drug therapy , Dexamethasone Isonicotinate/administration & dosage , Dexamethasone Isonicotinate/adverse effects , Dexamethasone Isonicotinate/therapeutic useABSTRACT
Las encefalopatías epilépticas se definen como los síndromes epilépticos en los que la actividad epiléptica per se (en forma de crisis frecuentes o presencia de actividad epileptiforme intercrítica) contribuye a un trastorno cognitivo y conductual mayor de lo esperable por la etiología del trastorno. Es fundamental un diagnóstico etiológico de ellas que nos permita un tratamiento precoz. Proponemos un algoritmo diagnóstico para los pacientes con encefalopatía epiléptica de inicio en el primer año de vida, en el que se incluye el abordaje coordinado de estudios electroencefalográficos, neuroimagen, y cribado de trastornos metabólicos y genéticos (AU)
Epileptic encephalopathies are defined as epileptic syndromes in which the epileptic activity per se (in the form of frequent seizures or the presence of interictal epileptiform activity) contributes to a cognitive and behavioural disorder thatis more important than could be expected from the causation of the disorder. Their aetiological diagnosis is fundamental to allow an early treatment to be established. We propose a diagnostic algorithm for patients with epileptic encephalopathy with onset during the first year of life, which includes management coordinated with electroencephalographic studies, neuroimaging, and screening for metabolic and genetic disorders (AU)
Subject(s)
Humans , Infant , Epilepsy/diagnosis , Epilepsy/therapy , Spasms, Infantile/diagnosis , Spasms, Infantile/therapy , Algorithms , Epilepsies, Myoclonic/diagnosis , Mass Screening/methods , Central Nervous System Diseases/complications , Medical History Taking , Electroencephalography/methods , Electroencephalography , 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase/therapeutic use , Biotin/therapeutic use , NeuroimagingABSTRACT
Introduction: Dravet syndrome (DS) is one of the most intractable forms of epilepsy that begins in infancy. This syndrome is characterized by beginning with complex febrile seizures (FS) in a healthy infant and progresses to refractory epilepsy with psychomotor regression. The detection of a SCN1A mutation encoding the sodium channel can confirm the diagnosis. Objective: To report 3 confirmed cases of genetically DS. Case reports: We describe 3 girls diagnosed with complex FS that started when they were between 2 and 7 months old. FS were frequent, hemi generalized and myoclonic associated with recurrent febrile status epilepticus (SE). Despite FS and SE recurrence, the psychomotor development, electrophysiological studies and magnetic resonance imaging (MRI) of the brain were normal. After a year, they developed afebrile seizures progressing to refractory epilepsy with developmental regression. A molecular study detected SCN1A mutation confirming DS. The specific antiepileptic treatment and prevention of febrile episodes allowed partial control of epilepsy with some recovery of psychomotor skills. Conclusions: The high frequency complex FS associated with recurrent SE in a previously healthy infant should alert about the possibility of DS. Molecular diagnostics helps us to establish a drugs and non-drug therapies treatment, as well as long-term prognosis and genetic counseling.
Introducción: El Síndrome de Dravet (SD) es una de las formas más intratables de epilepsia que debuta en lactantes con convulsiones febriles (CF) complejas recurrentes que evolucionan posteriormente a epilepsia refractaria con regresión psicomotora. La detección de una mutación del canal de Sodio (SCN1A) permite certificar el diagnóstico. Objetivo: Reportar 3 casos de SD confirmados genéticamente. Casos clínicos: Se describen 3 niñas con diagnóstico de CF complejas iniciadas entre los 2 y 7 meses de edad. Las CF eran frecuentes, hemigeneralizadas, mioclónicas asociadas a status epilepticus (SE) febriles recurrentes. A pesar de la recurrencia de CF y SE, tanto el desarrollo psicomotor como los estudios electrofisiológicos y la resonancia magnética (RM) cerebral, fueron normales. Posterior al año iniciaron crisis afebriles que evolucionaron a epilepsia refractaria con regresión del desarrollo. El estudio molecular detectó la mutación SCN1A confirmando SD. El tratamiento antiepiléptico específico y la prevención de cuadros febriles permitieron un control parcial de la epilepsia con recuperación de algunas habilidades psicomotoras. Conclusiones: La alta frecuencia de CF complejas asociadas a SE recurrentes en un lactante previamente sano, debe alertar sobre la posibilidad de un SD. El diagnóstico molecular nos permite instaurar un tratamiento antiepiléptico y terapias no farmacológicas además de un pronóstico a largo plazo y consejería genética.
Subject(s)
Child , Child, Preschool , Female , Humans , Infant , Anticonvulsants/therapeutic use , Epilepsies, Myoclonic/diagnosis , NAV1.1 Voltage-Gated Sodium Channel/genetics , Seizures, Febrile/diagnosis , Epilepsies, Myoclonic/drug therapy , Epilepsies, Myoclonic/genetics , Magnetic Resonance Imaging , Mutation , Status Epilepticus/diagnosisABSTRACT
Introducción: El síndrome de Dravet se caracteriza por una epilepsia resistente a fármacos de inicio en el primer año de vida con crisis con fiebre, y posterior evolución con déficit cognitivo y epilepsia con múltiples tipos de crisis. Habitualmente se diagnosticaba en torno a los 3-4 años de vida, pero el mejor conocimiento de las características de las crisis en los últimos años y el hallazgo de la alteración genética causal más frecuente han permitido adelantar el diagnóstico. Pacientes y métodos: Se presenta una serie de 14 niños diagnosticados de síndrome de Dravet o epilepsia del espectro Dravet. A las características de las crisis ocurridas durante el primer año de vida en estos pacientes, se aplican una serie de criterios de riesgo para ver si es posible hacer el diagnóstico en dicho período de tiempo. Resultados: en el 100% de los niños de esta serie se podía sospechar el diagnóstico en el primer año de vida aplicando estos criterios. Además, el 79% cumplían ya los criterios de riesgo en la primera crisis. Conclusiones: Es posible obtener un índice alto de sospecha de síndrome de Dravet en el primer año de vida. Es esencial, por tanto, la difusión de los criterios clínicos que permiten la sospecha diagnóstica temprana y la distinción de crisis febriles de otro origen, y el establecimiento de un protocolo de recogida de datos para las crisis con fiebre en el primer año de vida(AU)
Introduction: Dravet syndrome is a drug resistant epilepsy which starts in the first year of life with febrile seizures, followed by cognitive impairment and epilepsy with multiple seizure types. Diagnosis has been typically made at the age of three to four years, but earlier diagnosis is now possible as clinical features are better recognised and molecular diagnosis is available. Patients and methods: We studied a series of 14 children with Dravet syndrome or Dravet spectrum epilepsy. A screening test, developed by other authors to distinguish the febrile seizures in Dravet syndrome from febrile seizures from other origin, was applied to the clinical features of the seizures occurring during the first year of life in our patients. Results: Clinical suspicion of Dravet spectrum epilepsy was possible in 100% of children in our series. Moreover, taking into consideration only the first seizure, 79% of patients scored sufficiently to detect Dravet syndrome. Conclusions: Dravet syndrome can be recognised during the first year of life. It is important that physicians are made aware of these clinical criteria capable to distinguish febrile seizures in Dravet syndrome from febrile seizures of other origin, and set up a protocol to collect appropriate data regarding febrile seizures occurring in the first year of life(AU)
Subject(s)
Humans , Male , Female , Child , Epilepsies, Myoclonic/complications , Epilepsies, Myoclonic/diagnosis , Early Diagnosis , Fever/complications , Fever/etiology , Sensitivity and Specificity , Epilepsies, Myoclonic/physiopathology , Retrospective Studies , Odds Ratio , Myoclonus/complications , Myoclonus/diagnosisABSTRACT
El interés de los autores es llamar la atención sobre el síndrome opercular, y estimular con ello su identificación en la práctica neuropediátrica. Se realizó una búsqueda en PubMed desde febrero de 2005 hasta septiembre de 2010, y se comentaron los artículos que, a consideración de los autores, mostraban los diferentes aspectos del concepto, historia, características clínicas, causas, así como del diagnóstico, evolución y pronóstico. El síndrome opercular puede ser de causa congénita o adquirida; en los adultos es más frecuente por infarto cerebral opercular bilateral, no así en los niños, en los que se puede presentar por diferentes causas, desde trastornos de la migración neuroblástica, hasta en la epilepsia. En niños epilépticos se debe estar atento a su evolución, ya que tanto por el tipo de epilepsia o síndrome epiléptico, como por la medicación antiepiléptica usada, puede presentarse este síndrome, teniendo una gran significación su identificación rápida y tratamiento adecuado(AU)
The interest of authors is to attract attention on operculum syndrome and thus to stimulate its identification in the neuropediatric practice. A search in PubMed from February, 2005 to September, 2010 was made commenting on papers that according authors showed the different features of concept, history, clinical features, causes, as well as diagnosis, evolution and prognosis. The operculum syndrome may be congenital or acquired; ion adults is more frequent by bilateral operculum cerebral infarction, but not in children in whom it may be present by different causes, from neuroblast migration to epilepsy. In the case of epileptic children it is necessary to pay attention to its course since due to the type of epilepsy or epileptic syndrome or due to antiepileptic drug used, this syndrome may be present, considering very much its fast identification and appropriate treatment(AU)